- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01731912
Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer
Degarelix Acetate Prior to Radiation Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To evaluate the effect of neoadjuvant degarelix (degarelix acetate) on prostate dihydrotestosterone (DHT) and testosterone levels.
SECONDARY OBJECTIVES:
I. To determine the effect of degarelix acetate on androgen-regulated gene expression and apoptosis as assessed by immunohistochemistry, complementary deoxyribonucleic acid (cDNA) microarray analysis and reverse transcriptase (RT)-polymerase chain reaction (PCR).
II. To determine the effect of degarelix acetate on follicle stimulating hormone (FSH) and FSH receptor expression in prostate cancer and surrounding microenvironment.
OUTLINE:
Patients receive degarelix acetate subcutaneously (SC) on day 1. Treatment repeats every 4 weeks for up to 6 courses. Beginning at week 15, patients also undergo standard external beam radiation therapy (EBRT) for 8.5 weeks.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98109
- Fred Hutch/University of Washington Cancer Consortium
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Willing and able to provide written informed consent
- Written authorization for use and release of health and research study information has been obtained
- Histologically proven adenocarcinoma of the prostate
Patients must be candidates for short or long term androgen deprivation in combination with external beam radiation therapy (RT) based on the following criteria:
- Intermediate risk disease: T2b/c, or Gleason 7, or prostate-specific antigen (PSA) 10-20
- High risk disease: Gleason 8-10, or PSA > 20, or T3/4
- Patients may not have received any prior pharmacologic therapy or RT for prostate cancer
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
- Eligibility of patients receiving any medications or substances known to affect or with the potential to affect the androgen axis will be determined following review of their case by the principal investigator
- Patients must allow biopsy at the time of fiducial placement
Exclusion Criteria:
- Patients may not be receiving any investigational agents
- Patients who are currently receiving active therapy for other neoplastic disorders will not be eligible
- Patients with histologic evidence of small cell carcinoma of the prostate will not be eligible
- Patients with hypogonadism or severe androgen deficiency as defined by serum testosterone less than 100 ng/dL will not be eligible
- History of pituitary dysfunction
- Patients who are receiving any androgens, estrogens or progestational agents, or who received any of these agents within the 6 months prior to evaluation will not be eligible
- Patients who are taking drugs which affect androgen metabolism (e.g. spironolactone, ketoconazole, finasteride, dutasteride) will not be eligible; patients who received any of these agents within the 6 months prior to evaluation will be reviewed for eligibility by the principal investigator on a case by case basis
- Patients with inflammatory bowel disease or other autoimmune conditions which might affect the radiated colon or rectum
- Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, unstable angina pectoris, cardiac arrhythmia which is symptomatic or requires active therapy, recent deep venous thrombosis, pulmonary emboli, cerebrovascular accident or ischemia will not be eligible
- Patients with dementia/psychiatric illness/social situations that would limit compliance with study requirements or would prohibit the understanding and/or giving of informed consent will not be eligible
- Patients with medical conditions, which, in the opinion of the investigators, would jeopardize either the patient or the integrity of the data obtained will not be eligible
- Other active malignancy, except non-melanoma skin cancer and superficial bladder cancer
- Patients unwilling to use contraceptives while on study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (degarelix acetate, EBRT)
Patients receive degarelix acetate SC on day 1.
Treatment repeats every 4 weeks for up to 6 courses.
Beginning at week 15, patients also undergo standard EBRT for 8.5 weeks.
|
Correlative studies
Given SC
Other Names:
Undergo standard EBRT
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tissue Levels of DHT in Prostate Tissue as Measured by Mass Spectometry
Time Frame: At week 24
|
Differences in tissue androgen levels between this group and historical comparisons will be evaluated by performing a one-way analysis of variance (ANOVA), followed by pair-wise two-sample t-tests to determine which groups are statistically different.
|
At week 24
|
Tissue Levels of Testosterone in Prostate Tissue as Measured by Mass Spectometry
Time Frame: At week 24
|
At week 24
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Robert Montgomery, Fred Hutch/University of Washington Cancer Consortium
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 7846 (Other Identifier: Fred Hutch/University of Washington Cancer Consortium)
- P30CA015704 (U.S. NIH Grant/Contract)
- NCI-2012-02136 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- RAD2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Adenocarcinoma
-
Case Comprehensive Cancer CenterTerminatedAdenocarcinoma of Prostate | Adenocarcinoma of the Prostate Stage I | Adenocarcinoma of the Prostate Stage II | Adenocarcinoma of the Prostate Stage IIIUnited States
-
NRG OncologyNational Cancer Institute (NCI)Active, not recruitingStage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage I Prostate AdenocarcinomaUnited States, Canada, Puerto Rico
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)CompletedStage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage I Prostate AdenocarcinomaUnited States
-
Dana-Farber Cancer InstituteCompletedProstate Cancer | Adenocarcinoma of the Prostate Stage I | Adenocarcinoma of the Prostate Stage II | Adenocarcinoma of the Prostate Stage IIIUnited States
-
University of California, San FranciscoCompletedProstate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage III Prostate Adenocarcinoma AJCC v7 | Stage I Prostate Adenocarcinoma AJCC v7 | Stage II Prostate Adenocarcinoma AJCC v7United States
-
National Cancer Institute (NCI)Active, not recruitingCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Adenocarcinoma AJCC v7 | Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation | Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation | Prostate Adenocarcinoma With Neuroendocrine...United States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage II Prostate Adenocarcinoma | Stage I Prostate Adenocarcinoma
-
NRG OncologyNational Cancer Institute (NCI)Active, not recruitingProstate Adenocarcinoma | Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage I Prostate AdenocarcinomaUnited States, Canada, Switzerland
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage III Prostate Adenocarcinoma AJCC v7 | Stage II Prostate Adenocarcinoma AJCC v7 | Stage I Prostate Adenocarcinoma American Joint Committee on Cancer (AJCC) v7United States
-
Andrei IagaruCompletedStage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage IV Prostate AdenocarcinomaUnited States
Clinical Trials on Laboratory Biomarker Analysis
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States